Difference between revisions of "Section 7: Treatments for SARS-CoV-2 Infection (from DOI: 10.1007/s11886-020-01292-3) (Q10740)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: named entity (P78): tocilizumab (chemical - MeSH supplementary concept) (Q10973), #quickstatements; #temporary_batch_1592945455790)
 
(7 intermediate revisions by the same user not shown)
Property / occurs inProperty / occurs in
-
Q10356 (Deleted Item)
+
Property / part ofProperty / part of
-
Q10356 (Deleted Item)
+
Property / named entity
 +
Property / named entity: sarilumab (chemical - MeSH supplementary concept) / rank
 +
Normal rank
Property / named entity
 +
Property / named entity: eculizumab (chemical - MeSH supplementary concept) / rank
 +
Normal rank
Property / named entity
 +
Property / named entity: Adalimumab (chemical - MeSH descriptor) / rank
 +
Normal rank
Property / named entity
 +
Property / named entity: Acute Respiratory Distress Syndrome (disease - MeSH descriptor) / rank
 +
Normal rank
Property / named entity
 +
Property / named entity: Myocarditis (disease - MeSH descriptor) / rank
 +
Normal rank
Property / Collection or Dataset of Origin
 +
Property / Collection or Dataset of Origin: Pubtator Central BioC-JSON formatted article files / rank
 +
Normal rank

Latest revision as of 19:25, 24 June 2020

Publication: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response"published as Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32; DOI: 10.1007/s11886-020-01292-3
Language Label Description Also known as
English
Section 7: Treatments for SARS-CoV-2 Infection (from DOI: 10.1007/s11886-020-01292-3)
Publication: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response"published as Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32; DOI: 10.1007/s11886-020-01292-3

    Statements

    0 references
    0 references
    0 references
    0 references
    0 references